Trial
NCT01820325
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
Non-Small Cell Lunch Cancer
Intervention
Buparlisib
Why stopped
Due to DLTs/AEs safety profile considered challenging.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-11